Karen Colbert Maresso

TL;DR: A brief overview of the context for and special considerations of molecular prevention along with a discussion of the results from major randomized controlled trials is provided in this paper, where the authors provide a brief overview and discussion of their results.

TL;DR: Chemopreventive studies have provided new insights into early disease pathogenesis, stimulated new risk assessments and models, fostered important research in end point biomarkers, and led to 13 approved agents.

TL;DR: Notable progress includes hosting an obesity special conference, co-leading concerted national implementation efforts in HPV vaccination, and charting the future elimination of cancer disparities by integrating new science tools, discoveries and perspectives into community-engaged research.

TL;DR: Urinary PGE-M is an established indicator of systemic prostaglandin E2 production and has previously been demonstrated to predict risk of advanced colorectal neoplasia in a handful of studies, and has the potential to define subsets of the population that may derive greater chemopreventive benefit from NSAIDs, as well as to optimize the use of expensive and/or invasive screening tests.

TL;DR: This chapter focuses on the epidemiology of lifestyle risk factors and their associated interventions, as well as on the use of molecular preventive agents.